Hada A, Xiao Z
Pathogens. 2025; 14(2).
PMID: 40005486
PMC: 11858322.
DOI: 10.3390/pathogens14020109.
Chen Z, Yang C, Wang J, Wang B, He L, Liu Z
J Cancer. 2025; 16(4):1167-1180.
PMID: 39895781
PMC: 11786044.
DOI: 10.7150/jca.105586.
Wang Q, Yu M, Zhang S
Front Immunol. 2025; 15:1440830.
PMID: 39877377
PMC: 11772360.
DOI: 10.3389/fimmu.2024.1440830.
Luo X, Lv Y, Yang J, Long R, Qiu J, Deng Y
Front Med (Lausanne). 2025; 11:1480191.
PMID: 39748921
PMC: 11693687.
DOI: 10.3389/fmed.2024.1480191.
Ferkel S, Holman E, Sojwal R, Rubin S, Rogalla S
Neoplasia. 2024; 59:101091.
PMID: 39642846
PMC: 11665540.
DOI: 10.1016/j.neo.2024.101091.
Pan-cancer γδ TCR analysis uncovers clonotype diversity and prognostic potential.
Yu X, Song L, Cen L, Cao B, Tao R, Shen Y
Cell Rep Med. 2024; 5(10):101764.
PMID: 39368482
PMC: 11513832.
DOI: 10.1016/j.xcrm.2024.101764.
Progress of research on γδ T cells in colorectal cancer (Review).
Pan L, Zhou Y, Kuang Y, Wang C, Wang W, Hu X
Oncol Rep. 2024; 52(6).
PMID: 39364743
PMC: 11478060.
DOI: 10.3892/or.2024.8819.
Cancer immunotherapy by γδ T cells.
Hayday A, Dechanet-Merville J, Rossjohn J, Silva-Santos B
Science. 2024; 386(6717):eabq7248.
PMID: 39361750
PMC: 7616870.
DOI: 10.1126/science.abq7248.
Hepatocellular carcinoma cells induce γδ T cells through metabolic reprogramming into tumor-progressive subpopulation.
Xia J, Wang C, Li B
Front Oncol. 2024; 14:1451650.
PMID: 39309735
PMC: 11412793.
DOI: 10.3389/fonc.2024.1451650.
From bench to bedside: an interdisciplinary journey through the gut-lung axis with insights into lung cancer and immunotherapy.
Dora D, Szocs E, Soos A, Halasy V, Somodi C, Mihucz A
Front Immunol. 2024; 15:1434804.
PMID: 39301033
PMC: 11410641.
DOI: 10.3389/fimmu.2024.1434804.
γδ T-cells in human malignancies: insights from single-cell studies and analytical considerations.
Ng J, Sze Cheung A
Front Immunol. 2024; 15:1438962.
PMID: 39281674
PMC: 11392790.
DOI: 10.3389/fimmu.2024.1438962.
T cell factor 1 (TCF-1) defines T cell differentiation in colorectal cancer.
Tran K, Kumari A, Raghu D, Cox D, Goh S, Perini M
iScience. 2024; 27(9):110754.
PMID: 39280606
PMC: 11401206.
DOI: 10.1016/j.isci.2024.110754.
Potential of gamma/delta T cells for solid tumor immunotherapy.
Zhu D, Ren X, Xie W, Chen J, Liang S, Jiang M
Front Immunol. 2024; 15:1466266.
PMID: 39253082
PMC: 11381238.
DOI: 10.3389/fimmu.2024.1466266.
Loss of DOCK2 potentiates Inflammatory Bowel Disease-associated colorectal cancer via immune dysfunction and IFNγ induction of IDO1 expression.
Churchhouse A, Billard C, Suzuki T, Pohl S, Doleschall N, Donnelly K
Oncogene. 2024; 43(42):3094-3107.
PMID: 39242821
PMC: 11473400.
DOI: 10.1038/s41388-024-03135-9.
Neutralizing IL-38 activates γδ T cell-dependent antitumor immunity and sensitizes for chemotherapy.
da Silva P, Mora J, You X, Wiechmann S, Putyrski M, Garcia-Pardo J
J Immunother Cancer. 2024; 12(8).
PMID: 39209451
PMC: 11367332.
DOI: 10.1136/jitc-2023-008641.
Dysfunctional tumor-infiltrating Vδ1 + T lymphocytes in microsatellite-stable colorectal cancer.
Stary V, Pandey R, List J, Kleissl L, Deckert F, Kabiljo J
Nat Commun. 2024; 15(1):6949.
PMID: 39138181
PMC: 11322529.
DOI: 10.1038/s41467-024-51025-1.
A pan-cancer gamma delta T cell repertoire.
Yu X, Song L, Cen L, Cao B, Tao R, Shen Y
bioRxiv. 2024; .
PMID: 39091790
PMC: 11291071.
DOI: 10.1101/2024.07.18.604205.
Systematic Analysis of Human Colorectal Cancer scRNA-seq Revealed Limited Pro-tumoral IL-17 Production Potential in Gamma Delta T Cells.
Ran R, Trapecar M, Brubaker D
bioRxiv. 2024; .
PMID: 39071278
PMC: 11275756.
DOI: 10.1101/2024.07.18.604156.
Pan-cancer analysis of T-cell proliferation regulatory genes as potential immunotherapeutic targets.
Wei R, Xiao S, Zhao S, Guo W, Liu Y, Mullor M
Aging (Albany NY). 2024; 16(14):11224-11247.
PMID: 39068665
PMC: 11315386.
DOI: 10.18632/aging.205977.
An intestinal T17 cell-derived subset can initiate cancer.
Fesneau O, Thevin V, Pinet V, Goldsmith C, Vieille B, MHoma Soudja S
Nat Immunol. 2024; 25(9):1637-1649.
PMID: 39060651
PMC: 11362008.
DOI: 10.1038/s41590-024-01909-7.